Gonzalo Guzzo-Merello1, Javier Segovia1, Fernando Dominguez1, Marta Cobo-Marcos1, Manuel Gomez-Bueno1, Patricia Avellana1, Isabel Millan2, Luis Alonso-Pulpon1, Pablo Garcia-Pavia3. 1. Heart Failure and Cardiomyopathy Unit, Heart Failure and Heart Transplant Section, Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain. 2. Biostatistics Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain. 3. Heart Failure and Cardiomyopathy Unit, Heart Failure and Heart Transplant Section, Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain; Cardiovascular Development and Repair Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. Electronic address: pablogpavia@yahoo.es.
Abstract
OBJECTIVES: This study sought to determine the natural history of contemporary alcoholic cardiomyopathy (ACM), to compare it with that of idiopathic dilated cardiomyopathy (IDCM), and to identify risk factors for poor outcome. BACKGROUND: ACM is a common cause of dilated cardiomyopathy (DCM), but little is known about its natural history or the effect of reducing alcohol intake on disease progression. METHODS: We studied the clinical characteristics and outcomes of 94 consecutive patients with ACM and 188 with IDCM, evaluated over the period between 1993 and 2011. RESULTS: After a median follow-up of 59 months (interquartile range: 25 to 107 months), 14 ACM patients (15%) had died from cardiovascular causes (6 from heart failure and 8 from sudden cardiac death), 14 (15%) underwent heart transplantation, 35 (37%) experienced recovery in left ventricular function, and 31 (33%) remained clinically stable without improvement in systolic function. Transplantation-free survival was higher in ACM patients than in IDCM patients (p = 0.002), and ACM was associated with a favorable outcome on multiple analysis of the entire cohort (odds ratio [OR]: 0.4; 95% confidence interval [CI]: 0.2 to 0.8; p = 0.01). Independent predictors of death or heart transplantation in ACM identified by multiple logistic regression analysis were atrial fibrillation (OR: 9.7; 95% CI: 2.56 to 36.79; p = 0.001); QRS duration >120 ms (OR: 7.2; 95% CI: 2.02 to 26; p = 0.002), and lack of beta-blocker therapy (OR: 4.4; 95% CI: 1.35 to 14.49; p = 0.014). ACM patients who reduced their alcohol intake to moderate levels exhibited similar survival (p = 0.22) and cardiac function recovery (p = 0.8) as abstainers. CONCLUSIONS: ACM has a better prognosis than IDCM. Atrial fibrillation, QRS width >120 ms, and the absence of beta-blocker therapy identify patients with a poor outcome. Alcohol abstainers and those who reduce intake to a moderate degree show similar clinical outcomes.
OBJECTIVES: This study sought to determine the natural history of contemporary alcoholic cardiomyopathy (ACM), to compare it with that of idiopathic dilated cardiomyopathy (IDCM), and to identify risk factors for poor outcome. BACKGROUND: ACM is a common cause of dilated cardiomyopathy (DCM), but little is known about its natural history or the effect of reducing alcohol intake on disease progression. METHODS: We studied the clinical characteristics and outcomes of 94 consecutive patients with ACM and 188 with IDCM, evaluated over the period between 1993 and 2011. RESULTS: After a median follow-up of 59 months (interquartile range: 25 to 107 months), 14 ACM patients (15%) had died from cardiovascular causes (6 from heart failure and 8 from sudden cardiac death), 14 (15%) underwent heart transplantation, 35 (37%) experienced recovery in left ventricular function, and 31 (33%) remained clinically stable without improvement in systolic function. Transplantation-free survival was higher in ACM patients than in IDCM patients (p = 0.002), and ACM was associated with a favorable outcome on multiple analysis of the entire cohort (odds ratio [OR]: 0.4; 95% confidence interval [CI]: 0.2 to 0.8; p = 0.01). Independent predictors of death or heart transplantation in ACM identified by multiple logistic regression analysis were atrial fibrillation (OR: 9.7; 95% CI: 2.56 to 36.79; p = 0.001); QRS duration >120 ms (OR: 7.2; 95% CI: 2.02 to 26; p = 0.002), and lack of beta-blocker therapy (OR: 4.4; 95% CI: 1.35 to 14.49; p = 0.014). ACM patients who reduced their alcohol intake to moderate levels exhibited similar survival (p = 0.22) and cardiac function recovery (p = 0.8) as abstainers. CONCLUSIONS: ACM has a better prognosis than IDCM. Atrial fibrillation, QRS width >120 ms, and the absence of beta-blocker therapy identify patients with a poor outcome. Alcohol abstainers and those who reduce intake to a moderate degree show similar clinical outcomes.
Authors: Lisa A Farinelli; Daria Piacentino; Brittney D Browning; Barbara B Brewer; Lorenzo Leggio Journal: J Addict Nurs Date: 2021 Jan-Mar 01 Impact factor: 1.476
Authors: Antonio Mirijello; Luisa Sestito; Christian Lauria; Claudia Tarli; Gabriele Angelo Vassallo; Mariangela Antonelli; Cristina d'Angelo; Anna Ferrulli; Filippo Crea; Anthony Cossari; Lorenzo Leggio; Salvatore De Cosmo; Antonio Gasbarrini; Giovanni Addolorato Journal: Eur J Intern Med Date: 2022-04-10 Impact factor: 7.749
Authors: James S Ware; Almudena Amor-Salamanca; Upasana Tayal; Risha Govind; Isabel Serrano; Joel Salazar-Mendiguchía; Jose Manuel García-Pinilla; Domingo A Pascual-Figal; Julio Nuñez; Gonzalo Guzzo-Merello; Emiliano Gonzalez-Vioque; Alfredo Bardaji; Nicolas Manito; Miguel A López-Garrido; Laura Padron-Barthe; Elizabeth Edwards; Nicola Whiffin; Roddy Walsh; Rachel J Buchan; William Midwinter; Alicja Wilk; Sanjay Prasad; Antonis Pantazis; John Baski; Declan P O'Regan; Luis Alonso-Pulpon; Stuart A Cook; Enrique Lara-Pezzi; Paul J Barton; Pablo Garcia-Pavia Journal: J Am Coll Cardiol Date: 2018-05-22 Impact factor: 24.094